Subscribe to Search results

Dr Ludlam felt that he was not getting the supply of PFC material that had been agreed.

Published on:

At Edinburgh Haemophilia Centre, there was a reduction in the use of cryoprecipitate and an increase in the use of NHS concentrate, with both Factorate and Koate being used in larger quantities than before.

Published on:

At Edinburgh Haemophilia Centre, there was a further reduction in the use of cryoprecipitate and an increase in NHS concentrate; some commercial concentrate was also used.

Published on:

Professor Ludlam described his perception of non-A non-B Hepatitis as being that until the late 1980s it was seen as a "mild non-progressive condition, the first serious study on liver biopsy having been undertaken in 1985."

Published on:

The treating paediatricians of the San Francisco baby published a report, showing that the only possible alternative cause might be a primary immunodeficiency disorder and setting out why the clinical and laboratory findings suggested that a transmissible infectious agent had resulted in AIDS.

Published on:

Professor Ludlam realised that factor concentrates not only gave rise to a potential risk of non-A, non-B infection and a real risk of HIV infection, but could also give rise to a deterioration in the immune system.

Published on:

Professor Ludlam thought the link between HIV and a deterioration in the immune system had been recognised by the virologist Professor Tedder: that AIDS could occur as a result of the side effects of impurities in the concentrates.

Published on:

Professor Ludlam received the first results from an AIDS study of his and was surprised, perplexed, and puzzled as he had expected no problem with those who had been on Scottish PFC concentrate.

Published on:

At the Edinburgh Royal Infirmary, tests were undertaken using stored samples - where people were unaware their sera had been stored - both in relation to HIV testing and to Hepatitis B testing with second-generation tests.

Published on:

A meeting of SNBTS and haemophilia directors recorded Professor Ludlam saying cryoprecipitate was preferable for treating children because of AIDS, with Dr Hann concurring, but that a policy seemed to be emerging to use less cryoprecipitate for haemophilia A patients.

Published on:

Dr Tedder gave evidence that Professor Ludlam had a "clinical suspicion" which was why he had sent stored samples to Dr Tedder for testing in autumn 1984.

Published on:

By 26 October 1984, Professor Ludlam had learned that six patients with haemophilia had developed antibody to HTLV-3; by 2 November he had received further test results relating to sixteen patients.

Published on:

Professor Ludlam wrote to a colleague at the Royal Infirmary that "It has recently become apparent to me that some of our patients with haemophilia have antibody to HTLV III virus."

Published on:

Dr Craske explained that he was awaiting the results of biopsy studies being undertaken in Sheffield and at the Royal Free, and it was recorded that there were other studies underway or anticipated in Oxford and Manchester.

Published on:

UK Government announces interim compensation payments following Inquiry recommendation

Published on:

Professor Bloom stated it was "a matter for the individual Directors to decide." He referred to the minutes of the fifth meeting of Haemophilia Reference Centre Directors (January 1978) where it was agreed factor VIII concentrates were preferred for home therapy to cryoprecipitate.

Published on:

Professor Savidge stated "I think the majority of responsible physicians knew by the end of the 70s that large donor pool concentrates, whether it be for Factor 8 or Factor 9 were the cause of non-A/non-B hepatitis".

Published on:

Professor Savidge described UKHCDO in the 1970s and 1980s as an isolated and autonomous advisory body without formal affiliation with the NHS, any Royal College or learned society (eg: British Society on Haematology) with its own self appointed working parties.

Published on:

Professor Savidge stated "extra money when found was spent on the purchase of commercial imported factor VIII concentrate, usually from the US, in preference to the safer cryoprecipitate that was the recommend [sic] treatment of children and mild haemophilia patients (assuming failure with DDAVP) generally available (in some regions in excess).

Published on:

St Thomas' Hospital's annual return for 1976 showed that cryoprecipitate and NHS Factor 8 were the most used products.

Published on: